ENTERA BIO LTD

Company Overview

Entera Bio Ltd is a clinical‑stage biotechnology company developing oral peptide and protein therapies using its proprietary N‑Tab platform, with lead programs EB613 (oral PTH(1–34)) for osteoporosis and EB612 for hypoparathyroidism. EB613 completed a positive 161‑patient Phase 2 that met biomarker and BMD endpoints and the company is preparing a 24‑month registrational Phase 3 contingent on FDA/SABRE acceptance of Total Hip BMD as a surrogate; EB612 has supportive Phase 2a/PKPD data and orphan designation. The company is R&D‑focused (≈20 employees) and outsources large‑scale manufacturing to an FDA/EMA‑inspected UK CMO, relies on a collaboration with OPKO for peptide supply and co‑development, and holds IIA funding with attendant royalty/transfer constraints. Management is pre‑revenue, carries an accumulated deficit, and currently reports a limited cash runway (management expects funding into mid‑Q3 2026 absent new financing) with an auditor’s going‑concern paragraph.

Executive Compensation Practices

As a small, pre‑commercial biotech, Entera shows the typical compensation mix of modest cash pay and materially higher equity‑based awards — share‑based compensation rose materially to $2.56M in 2024 and is a meaningful component of G&A. Compensation decisions are likely tied to clinical and regulatory milestones (e.g., SABRE/FDA concurrence on BMD as a surrogate, Phase 3 start, OPKO collaboration triggers), so executives and key scientists often receive option/RSU grants with milestone or long‑term vesting to align incentives and conserve cash. Black‑Scholes inputs and valuation judgments noted in MD&A mean option pricing and expense recognition will be sensitive to volatility and the company’s going‑concern status, and management may favor equity grants or milestone bonuses over large cash raises while runway is constrained. Expect board and compensation committees to weigh dilution tradeoffs, IIA royalty/transfer restrictions, and collaboration economics when structuring retention and performance awards.

Insider Trading Considerations

Insiders at Entera are likely to rely on equity exercises and opportunistic sales for liquidity because cash compensation is limited and the company is pre‑revenue; monitor Form 4 filings for option exercises followed by open‑market sales to cover taxes or diversify. Material clinical and regulatory events (SABRE updates, Type A/FDA responses, Phase 3 initiation, OPKO milestone payments) create clear blackout and information asymmetry windows — insiders should (and likely will) avoid trading around these events, and any sales immediately after positive or negative news merit scrutiny. Because Entera has a small float, insider transactions can move the stock more than in larger biotechs; also watch for insider activity ahead of financings or dilutive transactions (equity raises, warrant financings, collaboration opt‑outs) as such trades may signal expectations about dilution. Finally, US reporting rules (Section 16/Form 4) apply to officers/directors notwithstanding the Israel HQ, and investors should look for 10b5‑1 plans or pre‑arranged sale programs that explain patterned insider sales.